AstraZeneca CFO Donates Shares to Charity

AstraZeneca ( (AZN) ) has shared an update.

On June 10, 2025, AstraZeneca’s Executive Director and Chief Financial Officer, Aradhana Sarin, donated 200 American Depositary Shares to charity, as announced by the company on June 12, 2025. This transaction, which involved shares representing half of an ordinary share each, reflects AstraZeneca’s commitment to social responsibility and may enhance its reputation among stakeholders.

The most recent analyst rating on (AZN) stock is a Hold with a $74.00 price target. To see the full list of analyst forecasts on AstraZeneca stock, see the AZN Stock Forecast page.

Spark’s Take on AZN Stock

According to Spark, TipRanks’ AI Analyst, AZN is a Outperform.

AstraZeneca’s overall stock score is driven by strong financial performance and positive earnings call outcomes, highlighting robust growth and strategic pipeline advancements. While technical indicators suggest neutrality, the valuation appears high, indicating limited upside potential given current prices.

To see Spark’s full report on AZN stock, click here.

More about AstraZeneca

AstraZeneca PLC is a global, science-led biopharmaceutical company based in Cambridge, UK. It focuses on the discovery, development, and commercialization of prescription medicines in areas such as Oncology, Rare Diseases, and BioPharmaceuticals, including Cardiovascular, Renal & Metabolism, and Respiratory & Immunology. AstraZeneca’s innovative medicines are sold in more than 125 countries and are used by millions of patients worldwide.

Average Trading Volume: 5,455,279

Technical Sentiment Signal: Strong Buy

Current Market Cap: $229B

See more insights into AZN stock on TipRanks’ Stock Analysis page.